Navigation Links
Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
Date:12/14/2009

the call is 86237542.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and submitted a New Drug Application submission in December 2009.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004. Any statement d
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
3. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
4. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
5. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
6. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
7. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
8. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
9. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... WESTMINSTER, Colo. , Dec. 19, 2014  Monarch ... (f/k/a Cannabis Kinetics Corp.) is pleased to provide this ... for continued growth in 2015. "Over this ... corporate goals and I am extremely proud to say ... diversified position today than it has ever been," stated ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... symptom control ... with combination therapy ... published study presents,data demonstrating that patients with Chronic Obstructive ... bronchodilation and symptom control when treated with a,combination of ...
... a Benefit,of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with ... ... a new analysis of the,Active Ulcerative Colitis Trials (ACT 1 and ... patients with moderately to severely active,ulcerative colitis (UC) receiving REMICADE(R) (infliximab) ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8
(Date:12/21/2014)... (PRWEB) December 21, 2014 Over the ... performance issues in hundreds of emergency departments across the ... Its findings have been translated into an innovative suite ... to correct deficiencies and enhance the patient experience. ... emergency physician staffing and management services for hospitals, announced ...
(Date:12/21/2014)... Theme and plugin developers ... plugin for Final Cut Pro X entitled ProMotion. , ... more with absolute ease.” Said Christiana Austin, CEO of ... needed to easily animate their media inside FCPX.” , ... users to animate pictures, videos, logos, and more with ...
(Date:12/21/2014)... CannabisClassifieds.com celebrates marijuana’s new legal place at the ... its kind, the site has provided its faithful users with ... running. It uniquely combines the benefits of platforms like ... to the masses. Assuring the potent herb’s followers it’s ... public approval. , Shane Chattin, Owner of Cannabis ...
(Date:12/21/2014)... 2014 Concept Plus, LLC. a SDB ... in Fairfax, VA., today announced it has been recognized ... list, which ranks the fastest growing government contracting small businesses ... 2013. , This is the first year that Concept Plus, ... 20 with a 95.92% compound annual growth rate. “For Concept ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a ... business has announced its bamboo flooring promotion for ... material from certified suppliers, and offers the best ... In the current promotion, all customers can enjoy ... they say they know BambooIndustry.com from press releases. ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2
... 26, 2011Young adults ages 19-29 are struggling to get the ... group, demonstrating the need for Affordable Care Act provisions, some ... it more affordable, according to a new Commonwealth Fund report. ... adults couldn,t afford the care they needed, meaning they didn,t ...
... After 17 years of researching traumatic stress with war-afflicted ... medical profession, Teresa McIntyre, a research professor in the ... Measurement and Statistics (TIMES), at the University of Houston ... school teachers in seventh and eighth grade. ...
... About 19 percent of U.S. adults aged 24 to 32 ... that they have the potentially life-threatening condition, new research reveals. ... slew of health problems, including coronary heart disease, heart failure, ... National Institutes of Health (NIH), found the risk for this ...
... 25 (HealthDay News) -- The Internet has put the world ... allowed banned or controlled substances to slip within their grasp, ... May 19 in Drug Testing and Analysis , looked ... ingredients other than those claimed and can be hazardous. These ...
... of oral chemotherapy continues to rise, researchers from Michigan State ... cancer-fighting medication, a significant clinical problem that can result in ... to be addressed by the health care community, said College ... is published in the May edition of Seminars in ...
... 2011) Researchers studying driving habits and accident rates among the ... on age while saying they would hand over the keys if ... to drive. "We are now exploring the idea of an ... away your keys at some point," said Emmy Betz, MD, MPH, ...
Cached Medicine News:Health News:Health reform essential to young adults: Nearly half can't afford needed health care 2Health News:Health reform essential to young adults: Nearly half can't afford needed health care 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 4Health News:New University of Houston research study links job stress in teachers to student achievement 2Health News:New University of Houston research study links job stress in teachers to student achievement 3Health News:Study Finds Almost 1 in 5 Young Adults Has High Blood Pressure 2Health News:Illegal Drugs Easy to Buy on the Internet, U.K. Study Finds 2Health News:Many patients fail to properly take oral chemo, leading to complications 2Health News:Study shows elderly drivers support competency tests 2
... tip is specially rounded, extra ... wound and manipulation in the ... flexible tubing 25cm, ID - ... annular rings start .85mm ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... This all digital single plane C-arm angiography ... cardiac imaging performance and an expansive range ... cardiac angiography to ECG triggered. ... Detector technology,State of the art dynamic Flat ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: